The next PII follow up (per the co. PR) will use the 100mg and HIGHER doses. They can do this since the 100mg dose was so well tolerated. The main endpoint in the current study wasn't reached because it was defined as a function of response from BOTH the 50 and 100 mg cohorts. For the purposes of a PIII trial uses nothing but the most effective dose that's meaningless.
Unless there's a bell curve effect (unlikely) you're very likely to see success in the next trial and the PIII after than. And no amount of bashing on a Yahoo board is going to discourage the institutional investors who will know this because it's their job to know it.